Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MC3R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Membrane Complex | MC3R Lentivirus Premade Particles High titer (>10^8 TU/ml), Puromycin selection, HEK293T packaged. Sequence Verified. Cell-based assays preserve GPCR conformation. |
View MC3R Products |
| Gene Delivery | MC3R Promise-ORF / Lentivirus Codon-optimized for mammalian expression, Endotoxin Controlled. Full-length ORF for stable cell lines. |
View MC3R Products |
| Benchmark Ab | Anti-MC3R Recombinant Antibody Recombinant positive control for expression validation. High Purity (>95%). |
View MC3R Products |
| Validator | MC3R siRNA Set For knockdown verification and specificity checks. |
View MC3R Products |
| Related Target: MC4R | MC4R Critical for subfamily counter-screening and selectivity profiling (56% homology). Avoid off-target safety risks. |
View MC4R Products |
| Related Target: POMC | POMC Endogenous precursor polypeptide for melanocortin pathway evaluation. |
View POMC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native GPCR Conformation | Lentivirus for Stable Cell Line generation ensures functional multispanning membrane presentation. High titer, sequence verified. |
| Subfamily Off-target (MC4R/MC1R) | Homolog panel cell lines efficiently generated; Sequence Verified ORFs. Human/Mouse/Cyno orthologs available for cross-reactivity elimination. |
| Functional Signaling (cAMP) | Stable expression lines in HEK293 background for robust Gs-coupled assay readouts. |
| Lack of Controls | Clinical Benchmark Antibodies included for FACS/IHC. |
| False Positives in Signaling Assays | Validated siRNA included for specificity checks and endogenous baseline depletion. |
Live MC3R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MC3R therapeutics is intensifying, with major players shifting focus from traditional non-selective peptides to highly specific small molecules and biased agonists. As first-generation therapies for obesity primarily targeted MC4R, the next wave of R&D is targeting MC3R for novel indications like disease-associated cachexia, systemic inflammation, and synergistic metabolic control. MC3R, distinct in its role in metabolic efficiency and cachexia, represents the next frontier.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists | Leading Pharma / Biotech | Cachexia, Metabolic Syndrome | Selectivity Assay (Need Lentivirus for MC3R/MC4R stable cells) |
| Peptide Therapeutics | Specialty Endocrine Biotechs | Inflammatory Diseases | Receptor Activation (cAMP assays on verified cell lines) |
| Monoclonal Antibodies | Emerging Innovators | Targeted Modulation | Binding Assays (Native conformation via stable cell expression) |
Target Biology & Key Mutations
MC3R (melanocortin 3 receptor) is a 7-transmembrane Gs-coupled GPCR involved in energy homeostasis, inflammation, and cachexia. According to UniProt (P41968), key mutations include:
- rs38271 (VAR_020070): exhibits ligand binding and signaling properties similar to wild-type.
- Obesity risk variant 1 (VAR_055000): completely lacks signaling in response to agonist stimulation.
- Obesity risk variant 2 (VAR_055001): also shows complete loss of signaling in vitro. These variants underscore the importance of functional validation using native conformation assays.